Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Wednesday, January 18th at 3:00 PM ETEDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc....
Pharmaceutical
Helsinn closes financing agreement with Oberland Capital
Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late- and commercial-stage oncology and rare...
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is...
Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine
Eflornithine method for use patent from Michigan State University/Corewell Health® relates to treating patients with rare Bachmann-Bupp SyndromePALO ALTO, Calif.,...
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational...
Sharps Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023
High-Value specialized prefillable syringe systems to accelerate revenue growth in 2023 and beyond Company to launch next generation specialty polymer-based...
InMed Provides Business Update and Milestones for 2023
Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human...
AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million
IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused...
Indegene expands Europe presence with new center in Germany to enable life sciences companies be future ready
FRANKFURT, Germany and PRINCETON, N.J. and BANGALORE, India, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization...
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
-- Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European...
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
Acquisition to enable creation of a fully integrated, enterprise-wide capability to discover, design and develop next-generation immunotherapies at scale by...
Syneos Health Dealmakers’ Intentions Survey Sees “Optimism” for M&A and Licensing Deals in 2023
Despite Uncertainties, Survey Hints that Dealmaking Intensity Could Be Poised for a Rebound After a Year of InertiaMORRISVILLE, N.C., Jan....
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
-- Dr. Stewart Brings More Than 30 Years of Cardiometabolic Academic and Industry Experience to Amarin’s Board –- -- Ongoing...
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
Calibre Scientific Acquires Dynalab, a U.S. Distributor and Manufacturer of Laboratory Supplies and Consumables
LOS ANGELES, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of Dynalab Corp. (the “Company”), a...
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single...
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
NGM Bio’s three-pronged corporate strategy includes the following components:Focus internal clinical development efforts on solid tumor oncology portfolioGenerate next-generation biologics...
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
Company is on track to move into the clinic with its lead targeted therapeutics programSAN DIEGO, Jan. 09, 2023 (GLOBE...
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with...
Merus Provides 2023 Outlook
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with...